AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20375178 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnephrectomy urine ADFP concentration in patients with clear cell or papillary cancer (n=25)
Number of subjects: 42
Study 20375178 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between tumor size and preexcision urine AQP1 concentration in patients with clear cell and papillary carcinoma
Number of subjects: 42
Study 20375178 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between tumor size and preexcision urine ADFP concentration in patients with clear cell and papillary carcinoma
Number of subjects: 42
Study 20375343 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injections
Number of subjects: 12
Study 20375733 — intervention group
Group type: EXPERIMENTAL
Intervention: FAS
Number of subjects: 78
Study 20375733 — intervention group
Group type: EXPERIMENTAL
Intervention: pFAS
Number of subjects: 78
Study 20375733 — intervention group
Group type: EXPERIMENTAL
Intervention: ARND
Number of subjects: 78
Study 20375733 — intervention group
Group type: COMPARATOR
Intervention: Control (pFAS and ARND)
Number of subjects: 78
Study 20377408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum samples from children with positive stool samples for Cryptosporidium
Number of subjects: 17
Study 20377408 — intervention group
Group type: COMPARATOR
Intervention: Sputum samples from children with negative stool samples for Cryptosporidium
Number of subjects: 17
Study 20377408 — intervention group
Group type: COMPARATOR
Intervention: Saliva samples from children tested for Cryptosporidium
Number of subjects: 17
Study 20378407 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat 300 mg once daily
Number of subjects: 16
Study 20378407 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat 400 mg once daily
Number of subjects: 16
Study 20378407 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (various doses)
Number of subjects: 16
Study 20378407 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat
Number of subjects: 16
Study 20378559 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute painful episodes
Number of subjects: 26
Study 20378559 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum amyloid A
Number of subjects: 26
Study 20378559 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-I
Number of subjects: 26
Study 20378559 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum amyloid A/apolipoprotein A-I ratio
Number of subjects: 26
Study 20378600 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory flow limitation (EFL) determined via the negative expiratory pressure (NEP) method
Number of subjects: 448
Study 20378600 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative expiratory pressure (NEP) method
Number of subjects: 448
Study 20378600 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory polygraphy (VP)
Number of subjects: 448
Study 20378616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganirelix (GnRH antagonist)
Number of subjects: 1000
Study 20378616 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (buserelin)
Number of subjects: 1000
Study 20378679 — intervention group
Group type: EXPERIMENTAL
Intervention: Home hip abductor strengthening program
Number of subjects: 40
Study 20378679 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants without knee OA)
Number of subjects: 40
Study 20378730 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) - 6 months of open-label, daily, self-administered INH.
Number of subjects: 1762
Study 20378730 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy (ART) - received by 480 participants.
Number of subjects: 1762
Study 20378730 — intervention group
Group type: COMPARATOR
Intervention: Alcohol use - defined by CAGE criteria.
Number of subjects: 1762
Study 20378730 — intervention group
Group type: COMPARATOR
Intervention: Age greater than 35 years and presence of hepatitis B virus core antibody.
Number of subjects: 1762
Study 20378927 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified slow-release oral testosterone
Number of subjects: 16
Study 20378927 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release oral testosterone
Number of subjects: 16
Study 20378927 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone with finasteride
Number of subjects: 16
Study 20378927 — intervention group
Group type: COMPARATOR
Intervention: Oral testosterone without finasteride
Number of subjects: 16
Study 20380712 — intervention group
Group type: EXPERIMENTAL
Intervention: de-novo CNI-free immunosuppression with basiliximab, mycophenolate sodium, prednisolone and everolimus
Number of subjects: 29
Study 20382691 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (waist circumference 88-93 cm)
Number of subjects: 42
Study 20382691 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (waist circumference 94-101 cm)
Number of subjects: 42
Study 20382691 — intervention group
Group type: COMPARATOR
Intervention: Group 4 (waist circumference 102 cm or greater)
Number of subjects: 42
Study 20383216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative conditioning regimen for hematopoietic cell transplantation (HCT)
Number of subjects: 6
Study 20384395 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine 5, 10 and 15 mg twice daily for 14 days
Number of subjects: 25
Study 20384962 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine
Number of subjects: 222
Study 20385792 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide-bortezomib-dexamethasone combination therapy
Number of subjects: 66
Study 20385942 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 ROP
Number of subjects: 294
Study 20385942 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 ROP with examination in <7 days
Number of subjects: 294
Study 20385942 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 ROP that continued at first follow-up examination
Number of subjects: 294
Study 20385942 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly examinations for type 2 ROP
Number of subjects: 294
Study 20386074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy (2 g/kg)
Number of subjects: 17
Study 20386909 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0457 (24-h continuous intravenous infusion at 64 mg/m(2)/h every 21 days)
Number of subjects: 27
Study 20386909 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0457 (100 mg oral dose administered 48 h prior to CIV infusion)
Number of subjects: 27
Study 20386909 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0457 (24-h continuous intravenous infusion)
Number of subjects: 27
Study 20390419 — intervention group
Group type: EXPERIMENTAL
Intervention: TSU-68 at a dose of 200 mg bid
Number of subjects: 35
Study 20391423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 400 mg/kg every 3 weeks from week 12 to week 24 of gestation
Number of subjects: 20
Study 20391423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 20
Study 20393117 — intervention group
Group type: EXPERIMENTAL
Intervention: SD-OCT
Number of subjects: 12
Study 20393117 — intervention group
Group type: COMPARATOR
Intervention: CFP
Number of subjects: 12
Study 20393132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine combined with ATRA and idarubicin in the first and third consolidation courses for high-risk patients.
Number of subjects: 372
Study 20393132 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose of mitoxantrone for the second consolidation course for low- and intermediate-risk patients.
Number of subjects: 372
Study 20393132 — intervention group
Group type: COMPARATOR
Intervention: LPA2005 trial (new trial)
Number of subjects: 372
Study 20393336 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port appendectomy (SA)
Number of subjects: 72
Study 20393336 — intervention group
Group type: COMPARATOR
Intervention: Three-port appendectomy (TA)
Number of subjects: 72
Study 20394026 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion (CII)
Number of subjects: 200
Study 20394026 — intervention group
Group type: COMPARATOR
Intervention: Continuous insulin infusion (CII) with oral intake
Number of subjects: 200
Study 20394321 — intervention group
Group type: COMPARATOR
Intervention: Sleep related breathing disorders (SRBD) diagnosed by apnea-hypopnea index (AHI) > 15 events/h, with 445 subjects (53%) diagnosed, and 167 subjects (37%) with AHI > 30.
Number of subjects: 827
Study 20394321 — intervention group
Group type: COMPARATOR
Intervention: Subjects with AHI > 30 (severe SRBD).
Number of subjects: 827
Study 20394321 — intervention group
Group type: COMPARATOR
Intervention: Subjects with AHI ≤ 15 (no SRBD).
Number of subjects: 827
Study 20394897 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain-encoded cardiac magnetic resonance (SENC)
Number of subjects: 80
Study 20394897 — intervention group
Group type: COMPARATOR
Intervention: Cine imaging
Number of subjects: 80
Study 20394897 — intervention group
Group type: EXPERIMENTAL
Intervention: SENC
Number of subjects: 80
Study 20395557 — intervention group
Group type: EXPERIMENTAL
Intervention: let-7d antagomir
Number of subjects: 20
Study 20395855 — intervention group
Group type: EXPERIMENTAL
Intervention: Components separation technique for hernia repair
Number of subjects: 19
Study 20398812 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermicol-P35 27G, 30G, or both
Number of subjects: 30
Study 20398872 — intervention group
Group type: EXPERIMENTAL
Intervention: JACTAX HD paclitaxel-eluting stent
Number of subjects: 103
Study 20398925 — intervention group
Group type: EXPERIMENTAL
Intervention: MDV3100 30 mg
Number of subjects: 140
Study 20398925 — intervention group
Group type: EXPERIMENTAL
Intervention: MDV3100 60 mg
Number of subjects: 140
Study 20398925 — intervention group
Group type: EXPERIMENTAL
Intervention: MDV3100 240 mg
Number of subjects: 140
Study 20398925 — intervention group
Group type: EXPERIMENTAL
Intervention: MDV3100 (various doses)
Number of subjects: 140
Study 20398925 — intervention group
Group type: EXPERIMENTAL
Intervention: MDV3100 (60 mg to 480 mg)
Number of subjects: 140
Study 20398925 — intervention group
Group type: EXPERIMENTAL
Intervention: MDV3100
Number of subjects: 140
Study 20398959 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination cream (hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%) daily for 12 weeks, then maintenance therapy twice per week for 12 weeks if clear or almost clear (cohort B)
Number of subjects: 70
Study 20398959 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination cream (hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%) daily for 24 weeks (cohort A)
Number of subjects: 70
Study 20398959 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination cream (hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%) daily for 12 weeks, then returned to daily dosing after relapse during maintenance (cohort C)
Number of subjects: 70
Study 20400682 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1 peptide vaccine (4 peptides, 200 microg each) with immune adjuvants, administered over 12 weeks (6 vaccinations)
Number of subjects: 9
Study 20400682 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1 peptide vaccine
Number of subjects: 9
Study 20400762 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin for up to 8 days
Number of subjects: 20275
Study 20400762 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) for 48 h
Number of subjects: 20275
Study 20400762 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 20275
Study 20400762 — intervention group
Group type: COMPARATOR
Intervention: UFH
Number of subjects: 20275
Study 20402989 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interview with Personalized Feedback (MI)
Number of subjects: 172
Study 20402989 — intervention group
Group type: COMPARATOR
Intervention: Feedback Only (FO)
Number of subjects: 172
Study 20403849 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery
Number of subjects: 102
Study 20403855 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic primary surgery
Number of subjects: 36
Study 20403855 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic salvage surgery
Number of subjects: 36
Study 20403855 — intervention group
Group type: COMPARATOR
Intervention: Open salvage surgery
Number of subjects: 36
Study 20403857 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-induced sleep endoscopy with intravenous propofol infusion
Number of subjects: 108
Study 20404380 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral MRI with angiography performed up to 7 days after admission and before any surgical intervention.
Number of subjects: 130
Study 20406267 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE genotype (allele ∗2)
Number of subjects: 25
Study 20406267 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE genotype (allele ∗4)
Number of subjects: 25
Study 20406267 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE genotype (∗3∗3)
Number of subjects: 25
Study 20407111 — intervention group
Group type: EXPERIMENTAL
Intervention: MB stent implantation
Number of subjects: 77
Study 20407111 — intervention group
Group type: EXPERIMENTAL
Intervention: Preintervention % diameter stenosis of the SB
Number of subjects: 77
Study 20407111 — intervention group
Group type: EXPERIMENTAL
Intervention: MB minimum lumen diameter located distal to the SB ostium
Number of subjects: 77
Study 20407111 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with > or =75% stenosis and Thrombolysis In Myocardial Infarction grade 3 flow in the SB
Number of subjects: 77
Study 20407116 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 20408846 — intervention group
Group type: EXPERIMENTAL
Intervention: ofatumumab (4 weekly infusions)
Number of subjects: 33
Study 20409549 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation
Number of subjects: 450
Study 20409626 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubo Collar
Number of subjects: 30
Study 20410100 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs in apolipoprotein J (APOJ)
Number of subjects: 761
Study 20410100 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs in lipoprotein lipase (LPL)
Number of subjects: 761
Study 20410100 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs in tumor necrosis factor receptor superfamily member 10b (TNFRSF10B)
Number of subjects: 761
Study 20410100 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative genetic analyses
Number of subjects: 761
Study 20410100 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide scan for plasma fatty acids
Number of subjects: 761
Study 20412178 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 600 mg/d for 14 days
Number of subjects: 210
Study 20412178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 20413029 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HF device diagnostics (positive criteria: long atrial fibrillation duration, rapid ventricular rate during atrial fibrillation, high fluid index, low patient activity, abnormal autonomics, notable device therapy, or very high fluid index)
Number of subjects: 694
Study 20413029 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HF device diagnostics (positive criteria)
Number of subjects: 694
Study 20413039 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 272
Study 20413436 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonperinatal patients (symptomatic beyond 1 month)
Number of subjects: 73
Study 20413436 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal patients
Number of subjects: 73
Study 20413436 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonperinatal patients
Number of subjects: 73
Study 20413436 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticomedullary involvement on HR-USG
Number of subjects: 73
Study 20413436 — intervention group
Group type: EXPERIMENTAL
Intervention: Medullary involvement only
Number of subjects: 73
Study 20413436 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with enlarged kidneys
Number of subjects: 73
Study 20413436 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with medullary-only abnormalities
Number of subjects: 73
Study 20413540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 316
Study 20413540 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 6MWD
Number of subjects: 316
Study 20413540 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC score
Number of subjects: 316
Study 20413540 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial carbon dioxide tension
Number of subjects: 316
Study 20413540 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of osteoporosis
Number of subjects: 316
Study 20413658 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1 mutations
Number of subjects: 842
Study 20413658 — intervention group
Group type: COMPARATOR
Intervention: No WT1 mutations
Number of subjects: 842
Study 20413658 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1 mutations without FLT3/ITD
Number of subjects: 842
Study 20413658 — intervention group
Group type: COMPARATOR
Intervention: Wild type for both mutations
Number of subjects: 842
Study 20413687 — intervention group
Group type: EXPERIMENTAL
Intervention: 4SC-101 (300 mg/kg)
Number of subjects: 0
Study 20413687 — intervention group
Group type: COMPARATOR
Intervention: CYC (30 mg/kg/week, i.p.)
Number of subjects: 0
Study 20413687 — intervention group
Group type: EXPERIMENTAL
Intervention: 4SC-101 (30 mg/kg, 100 mg/kg)
Number of subjects: 0
Study 20413687 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 20413733 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment with LDLR haplotype 5 (LDLR L5) in blacks
Number of subjects: 944
Study 20413733 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment with combined LDLR L5 and HMGCR haplotypes in blacks
Number of subjects: 944
Study 20413733 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment measuring LDL receptor surface expression
Number of subjects: 944
Study 20418368 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Doppler echocardiography (EDE)
Number of subjects: 52
Study 20418368 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET)
Number of subjects: 52
Study 20418368 — intervention group
Group type: COMPARATOR
Intervention: Right-sided heart catheterization (RHC)
Number of subjects: 52
Study 20418368 — intervention group
Group type: COMPARATOR
Intervention: EDE vs RHC
Number of subjects: 52
Study 20418368 — intervention group
Group type: EXPERIMENTAL
Intervention: EDE
Number of subjects: 52
Study 20418368 — intervention group
Group type: EXPERIMENTAL
Intervention: EDE + CPET
Number of subjects: 52
Study 20418798 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 count criteria for initiating antiretroviral therapy
Number of subjects: 446
Study 20418798 — intervention group
Group type: EXPERIMENTAL
Intervention: Current CD4 count criteria
Number of subjects: 446
Study 20420675 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to organic or inorganic allergenic or irritant compounds
Number of subjects: 250
Study 20420675 — intervention group
Group type: COMPARATOR
Intervention: No specific occupational exposure (control group)
Number of subjects: 250
Study 20420716 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention
Number of subjects: 58
Study 20420716 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 58
Study 20421061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine analysis for IL-2, -8, -10, and granulocyte macrophage-colony stimulating factor in infected patients.
Number of subjects: 1655
Study 20421061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine analysis for IL-6, -8, and IL-10 in noninfected nontrauma patients.
Number of subjects: 1655
Study 20421061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine analysis for IL-4, -6, -8, and TNF-alpha in trauma patients.
Number of subjects: 1655
Study 20421061 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-4 in trauma patients.
Number of subjects: 1655
Study 20421061 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-8 in nontrauma, noninfected patients.
Number of subjects: 1655
Study 20421061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine analysis in infected patients.
Number of subjects: 1655
Study 20421274 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 0
Study 20421452 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (30 to 40 mg/kg per day)
Number of subjects: 28
Study 20421455 — intervention group
Group type: EXPERIMENTAL
Intervention: IDH2 mutations present (12.1% of CN-AML patients)
Number of subjects: 272
Study 20421455 — intervention group
Group type: COMPARATOR
Intervention: IDH2 mutations absent (majority of CN-AML patients)
Number of subjects: 272
Study 20421455 — intervention group
Group type: EXPERIMENTAL
Intervention: IDH2 mutations in AML patients with aberrant karyotypes (n = 130)
Number of subjects: 272
Study 20422738 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril and indapamide
Number of subjects: 11140
Study 20422738 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril-indapamide and gliclazide MR-based regimen
Number of subjects: 11140
Study 20422738 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril and indapamide and gliclazide-MR-based regimen
Number of subjects: 11140
Study 20424554 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 -572C/G polymorphism
Number of subjects: 212
Study 20424554 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 -1082A/G polymorphism
Number of subjects: 212
Study 20424554 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha -308G/A polymorphism
Number of subjects: 212
Study 20424554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of circulating concentrations of IL-10/IL-6
Number of subjects: 212
Study 20424554 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without acute lung injury)
Number of subjects: 212
Study 20426845 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin like growth factor-I (IGF-I) in patients with aSAH, mean IGF-I concentrations for days one to five were 8.1 +/- 3.5 nmol/l.
Number of subjects: 30